Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer

FRIDAY, June 12, 2026-- For patients with localized prostate cancer, aglatimagene besadenovec, an adenoviral-based immunotherapy, plus valacyclovir is associated with longer disease-free survival (DFS) than placebo plus valacyclovir when added to...